Otilimab Biosimilar – Anti-CSF2, GM-CSF mAb – Research Grade

Description of Otilimab Biosimilar - Anti-CSF2, GM-CSF mAb - Research Grade

Otilimab Biosimilar – Anti-CSF2, GM-CSF mAb – Research Grade: A Promising Therapeutic Antibody Targeting GM-CSF

Introduction

Otilimab Biosimilar, also known as Anti-CSF2 or GM-CSF mAb, is a monoclonal antibody (mAb) that specifically targets the cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF). This biosimilar is a promising therapeutic agent with potential applications in various inflammatory and autoimmune diseases. In this article, we will delve into the structure, activity, and potential applications of Otilimab Biosimilar.

Structure of Otilimab Biosimilar

Otilimab Biosimilar is a recombinant humanized IgG1 monoclonal antibody that is derived from a mouse anti-human GM-CSF antibody. It consists of two identical heavy chains and two identical light chains, each with a molecular weight of approximately 50 kDa. The antibody has a Y-shaped structure, with two antigen-binding fragments (Fab) and one crystallizable fragment (Fc). The Fab region is responsible for binding to GM-CSF, while the Fc region mediates effector functions such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).

Activity of Otilimab Biosimilar

GM-CSF is a pro-inflammatory cytokine that plays a crucial role in the development and activation of immune cells, such as neutrophils, macrophages, and dendritic cells. It is also involved in the pathogenesis of various inflammatory and autoimmune diseases, including rheumatoid arthritis, multiple sclerosis, and psoriasis. Otilimab Biosimilar specifically binds to GM-CSF, preventing it from binding to its receptor and exerting its pro-inflammatory effects. This leads to a reduction in the activation and recruitment of immune cells, ultimately resulting in the suppression of inflammation.

Potential Applications of Otilimab Biosimilar

Otilimab Biosimilar has shown promising results in preclinical and clinical studies for the treatment of various inflammatory and autoimmune diseases. In a phase II clinical trial, Otilimab Biosimilar was found to be effective in reducing the signs and symptoms of rheumatoid arthritis, with a significant improvement in disease activity and joint damage. It has also shown potential for the treatment of other inflammatory conditions, such as psoriasis and asthma.

In addition to its potential as a therapeutic agent, Otilimab Biosimilar also has applications in research. Its ability to specifically target GM-CSF makes it a valuable tool for studying the role of this cytokine in different diseases. It can also be used to investigate the mechanisms of action of other GM-CSF targeting therapies and to identify potential biomarkers for response to treatment.

Advantages of Otilimab Biosimilar

One of the main advantages of Otilimab Biosimilar is its high specificity for GM-CSF, which minimizes the risk of off-target effects and reduces the potential for adverse reactions. Its humanized structure also reduces the risk of immunogenicity, making it a safe and well-tolerated treatment option. Additionally, as a biosimilar, Otilimab Biosimilar offers a more cost-effective alternative to the originator antibody, making it more accessible to patients.

Conclusion

In conclusion, Otilimab Biosimilar – Anti-CSF2, GM-CSF mAb – Research Grade is a promising therapeutic antibody that specifically targets GM-CSF. Its structure, activity, and potential applications make it a valuable tool in the treatment and research of various inflammatory and autoimmune diseases. With ongoing clinical trials and further research, Otilimab Biosimilar has the potential to provide a more targeted and effective treatment option for patients in need.

Otilimab Biosimilar - Anti-CSF2, GM-CSF mAb binds to Human CSF2/GM-CSF in indirect ELISA Assay

Immobilized CSF2 / GM-CSF (in Mammalian), C-His, recombinant protein (cat. No. PX-P5667) at 0.5µg/mL (100µL/well) can bind Otilimab Biosimilar - Anti-CSF2, GM-CSF mAb (cat. No. PX-TA1141) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450 giving an EC50 at 152.1M.